On Sept. 8, 2021, National Resilience, a company seeking to build the world’s most advanced biopharmaceutical manufacturing ecosystem, and Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics, announced an agreement to manufacture mRNA for the Moderna COVID-19 vaccine.

Under the terms of the multi-year agreement, Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario, for distribution worldwide.

Resilience is a manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions with the aim to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to offer the highest quality and regulatory capabilities, and flexible and adaptive facilities to serve partners of all sizes. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience aims to free partners to focus on the discoveries that improve patients’ lives.